Bone Mineral Density and Serum Levels of Bone Remodeling Markers in Ankylosing Spondylitis Treated with Anti TNF-α Agents
Medical Sciences · 2025
DOI: 10.3390/medsci13030189 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Sciences, 2025. Verfasst von Efren Gerardo Alvarez-Ayala und 15 weiteren Autor:innen. Beteiligte Einrichtung: Programa de Doctorado en Farmacología, Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalaj…. Hauptthemen laut MEDLINE: Spondylitis, Ankylosing, Bone Density, Bone Remodeling, Tumor Necrosis Factor-alpha. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidad de Guadalajara, University of Guadalajara.
Abstract (Originalsprache)
Background
Ankylosing spondylitis (AS) is a chronic autoinflammatory rheumatic disease mainly affecting the sacroiliac joints and spine, causing altered bone remodeling. Pro-inflammatory cytokines such as TNF-α and IL-17 contribute to bone loss by modulating pathways including Wnt/β-catenin, which is inhibited by proteins like Dickkopf-1 (DKK-1) and sclerostin (SOST). Bone morphogenetic protein-6 (BMP-6) promotes osteoblast differentiation and bone formation. This study evaluated the association between serum levels of DKK-1, SOST, BMP-6, and bone mineral density (BMD) in AS patients treated with anti-TNF agents and conventional synthetic DMARDs (csDMARDs).
Methods
A cross-sectional study included 76 AS patients diagnosed by modified New York criteria and 30 healthy donors matched by age and sex. BMD at the lumbar spine and hips was assessed by DXA in all participants. Disease activity (BASDAI) and functional index (BASFI) were measured in AS patients. Serum levels of DKK-1, SOST, BMP-6, TNF-α, and IL-17 were quantified by ELISA in both groups. AS patients were divided into two treatment groups: combined anti-TNFα and csDMARD therapy (n = 38), and only csDMARDs (n = 38).
Results
Bone mineral density showed no significant statistical differences between the spine (p = 0.930) and hips (p = 0.876) in AS patients compared to healthy controls. The activity (BASDAI) and functionality (BASFI) scores were similar in both treatment groups (p = 0.161 and p = 0.271, respectively). No significant differences were found in serum levels of DKK-1 (p = 0.815), SOST (p = 0.771), BMP-6 (p = 0.451), or IL-17 (p = 0.335) between combined anti-TNFα and csDMARD therapy versus monotherapy with csDMARD.
Conclusions
The combination of anti-TNF bDMARD therapy and csDMARD therapy is not significantly associated with serum levels of DKK-1, SOST, BMP-6, and BMD compared to those treated with csDMARD monotherapy in patients with AS. This study provides novel and clinically relevant evidence on how anti-TNF bDMARDs and csDMARDs differentially affect bone turnover biomarkers and bone health in patients with AS, contributing to a better understanding of therapeutic strategies and guiding future research and clinical decision-making.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Programa de Doctorado en Farmacología, Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.
- Instituto de Terapéutica Experimental y Clínica, Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.
- Programa de Maestría en Salud Pública, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.
- Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.
- Unidad de Investigación Biomédica 02, UMAE, Hospital de Especialidades, Centro Médico Nacional de Occidente, IMSS, Guadalajara 44349, Mexico.
- Instituto de Investigación en Ciencias Biomédicas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.
ORCID-Profile: Efren Gerardo Alvarez-Ayala, Jorge Ivan Gamez-Nava, Ana Miriam Saldaña-Cruz, Fabiola Gonzalez-Ponce, Betsabe Contreras-Haro, Melissa Ramirez-Villafaña, Edsaul Emilio Perez-Guerrero, Miriam Fabiola Alcaraz-Lopez, Eli Efrain Gomez-Ramirez, Juan Manuel Ponce-Guarneros, Norma Alejandra Rodriguez-Jimenez, Sylvia Elena Totsuka-Sutto, Alberto Daniel Rocha-Muñoz, Luis Alfonso Muñoz-Miranda, Laura Gonzalez-Lopez, Cesar Arturo Nava-Valdivia
Förderung
- Universidad de Guadalajara
- University of Guadalajara
Zitieren
APA
Alvarez-Ayala, E. G., Gamez-Nava, J. I., Saldaña-Cruz, A. M., Gonzalez-Ponce, F., Contreras-Haro, B., Ramirez-Villafaña, M., Perez-Guerrero, E. E., Alcaraz-Lopez, M. F., Gomez-Ramirez, E. E., Ponce-Guarneros, J. M., Rodriguez-Jimenez, N. A., Totsuka-Sutto, S. E., Rocha-Muñoz, A. D., Muñoz-Miranda, L. A., Gonzalez-Lopez, L., & Nava-Valdivia, C. A. (2025). Bone Mineral Density and Serum Levels of Bone Remodeling Markers in Ankylosing Spondylitis Treated with Anti TNF-α Agents. Medical Sciences. https://doi.org/10.3390/medsci13030189
Vancouver
Alvarez-Ayala EG, Gamez-Nava JI, Saldaña-Cruz AM, Gonzalez-Ponce F, Contreras-Haro B, Ramirez-Villafaña M, et al. Bone Mineral Density and Serum Levels of Bone Remodeling Markers in Ankylosing Spondylitis Treated with Anti TNF-α Agents. Medical Sciences. 2025. doi:10.3390/medsci13030189
BibTeX
@article{AlvarezAyala2025,
author = {Alvarez-Ayala, Efren Gerardo and Gamez-Nava, Jorge Ivan and Saldaña-Cruz, Ana Miriam and Gonzalez-Ponce, Fabiola and Contreras-Haro, Betsabe and Ramirez-Villafaña, Melissa and Perez-Guerrero, Edsaul Emilio and Alcaraz-Lopez, Miriam Fabiola and Gomez-Ramirez, Eli Efrain and Ponce-Guarneros, Juan Manuel and Rodriguez-Jimenez, Norma Alejandra and Totsuka-Sutto, Sylvia Elena and Rocha-Muñoz, Alberto Daniel and Muñoz-Miranda, Luis Alfonso and Gonzalez-Lopez, Laura and Nava-Valdivia, Cesar Arturo},
title = {Bone Mineral Density and Serum Levels of Bone Remodeling Markers in Ankylosing Spondylitis Treated with Anti TNF-α Agents},
journal = {Medical Sciences},
year = {2025},
doi = {10.3390/medsci13030189}
}
EUVIMED